Luxury Aesthetics Reimagined: Beauty Factory LV Launches Cutting-Edge Morpheus8 RF Microneedling and Signature Sculpting Treatments
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/9586/258851_bfms_550.jpg ]
Figure 1: Beauty Factory
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9586/258851_bfms.jpg
A Revolution in Skin Rejuvenation
At the forefront of the launch is the Morpheus8 Advanced RF Microneedling treatment—a breakthrough technology that blends deep microneedling with targeted radiofrequency energy. This premium, minimally invasive service is designed to lift, tighten, and rejuvenate the skin, making it ideal for contouring the jawline, smoothing fine lines, and revitalizing aging or dull complexions.
'This is not your average facial,' said Maise Pastrano, a representative for Beauty Factory LV. 'With Morpheus8, our clients can achieve sculpted, youthful results with clinical precision—without going under the knife.'
Injectable Artistry with Natural Elegance
Complementing the Morpheus8 treatment, Beauty Factory LV now offers precision dermal fillers focused on facial contouring—particularly the chin and lips. These bespoke injectables are tailored to each client's anatomy, enhancing facial harmony while maintaining a natural look.
Recent client transformations—highlighted across the brand's Instagram—showcase the subtle yet striking outcomes from expertly placed fillers, further solidifying Beauty Factory LV's reputation as a go-to for natural refinement.
Botox Beyond Beauty: TMJ & Jaw Slimming Treatments
In addition to cosmetic enhancements, Beauty Factory LV is also offering Botox for TMJ relief and jaw slimming. This innovative, non-invasive treatment helps reduce jaw tension while subtly refining the lower face—merging wellness and aesthetics in a seamless experience.
About Beauty Factory LV
Beauty Factory LV is a boutique medical aesthetics studio based in Las Vegas, specializing in advanced, non-surgical cosmetic treatments that blend science, luxury, and artistry. Known for delivering elite-level care in a serene, client-first environment, the studio continues to raise the bar in modern beauty.
For media inquiries, appointments, or before-and-after galleries, follow Beauty Factory LV on Instagram or www.beautyfactorymedspa.com.
Name - Judy Schuler, CFO
Number - +1 702-352-3560
E-mail - [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258851
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
This Is The One "Superfood" You Should Always Eat At Breakfast, According To An Expert
From Apple Jacks to cheese omelettes, blueberry pancakes to leftover pizza, there are a zillion and one potential choices for breakfast these days. But some options are definitely more nutrient-rich than others. So what would a dietitian's No. 1 pick be? And how can we get more good stuff into our bodies first thing in the morning without sacrificing deliciousness? That's the question that we — Raj Punjabi and Noah Michelson, the hosts of HuffPost's Am I Doing It Wrong? podcast ― had for Lisa Moskovitz, a registered dietitian, certified dietitian-nutritionist and the CEO of NY Nutrition Group, when she dropped by our studio to offer her tips and tricks for doing breakfast better. Listen to the full episode here. Moskovitz's breakfast all-star is chia seeds, which are harvested from Salvia hispanica, a member of the mint family. Related: Related: 'It's a superfood because of all of the nutritional properties that it has, from fiber and magnesium to B vitamins and iron, and there's a little protein in there,' the author of The Core 3 Healthy Eating Plan told us. They also contain omega-3 fatty acids, which help keep our brains and hearts healthy and have been shown to reduce inflammation. 'It's great for regulating digestion,' Moskovitz added, 'so for people that struggle ... with constipation and regularities, chia seeds are a great source of insoluble and soluble fiber.' In fact, just one serving of chia seeds — typically two to three tablespoons — offers nearly 10 grams of fiber, which is one-third of the recommended daily intake for most people. Fiber not only helps with digestion by bulking and softening stools; it's been found to lower the risk for many dangerous health conditions, including heart disease, diabetes and some cancers. Chia seeds are also incredibly versatile and can be easily added to countless breakfast favorites to boost their nutritional benefits. 'You can sprinkle them in your yogurt, you can put them in your oatmeal, you can even sprinkle them on your avocado toast, in your eggs, in your coffee, and you can just take them in water,' Moskovitz suggested. 'You can soak them in your almond milk or dairy milk or any or oat milk and leave them in the fridge overnight, and that's a great grab-and-go.' By making tiny tweaks — including adding chia seeds or other nutrient-packed foods like nuts and fruit — to our tried and true breakfast go-tos, we can score more of what our bodies need without missing out on our morning favorites. 'Stop worrying about what to cut out and just think about what we can add in,' she advised. Moskovitz also chatted with us about the ideal time to eat breakfast, what to know before you eat another egg, the four things to add to every smoothie, and much more. Listen to the full episode wherever you get your podcasts. Make sure to subscribe to so you don't miss a single episode, including how to find love online or ; tips for , taking care of your teeth and ; secrets to ; how to ; shocking ; ; getting ; dealing with ; how to prevent ; boosting ; and much more. For more from Lisa Moskovitz, visit NY Nutrition Group and follow her on Instagram. Need some help with something you've been doing wrong? Email us at AmIDoingItWrong@ and we might investigate the topic in an upcoming article originally appeared on HuffPost. Also in Goodful: Also in Goodful: Also in Goodful:
Yahoo
24 minutes ago
- Yahoo
Northern California officials issue unsafe water alert, do not drink
( — A community in Northern California was issued an unsafe water alert and warned not to drink tap water because of possible bacterial contamination. On July 19, the Elk Creek Community Services District advised customers in Glenn County to use only bottled water for drinking, mixing baby formula, brushing teeth, washing dishes, making ice, and all other food preparation until further notice. Officials said a broken water main caused water pressure to drop below the minimum required, which would cause the water to be contaminated with coliform bacteria. Cliff jumper dies at Northern California lake after hitting water face-first 'We will inform you when tests show that the water is safe again,' ECCSD said in the advisory. 'We expect to resolve the bacteria contamination question within a few days.' Officials said the warning is a precautionary measure, and customers should not try to treat the water on their own. According to ECCSD, the water is safe for bathing and toilet use. For more information, customers can contact the ECCSD water plant operator, Jon Albertsen, at 707-489-1274 or the board president, Sharon Green, at 530-934-6588. Additionally, people who are concerned about their health can contact the Glenn County Public Health Department at 530-934-6588. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
32 minutes ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
